spacer
home > ebr > summer 2003 > the biotech juggling act
PUBLICATIONS
European Biopharmaceutical Review

The Biotech Juggling Act

The completed sequencing of the human genome was a tremendous achievement but only 30 months later, the long-term knock on to the drug discovery industry is becoming apparent. The prediction is that by 2005 about half of all new products will come out of biotech; presumably this is why there are over 4,000 biotech-focused companies (approximately 10 per cent of which are public) out there.

Throughout these organisations computer-based research studies are increasing, and notably they are developing independently of the laboratory. Well-integrated information systems (IS) may one day develop into the primary R&D environment, with analytical laboratories reduced to a secondary role of investigative analysis and manufacturing. Consequently, I find myself wondering: how long before computer-based research overhauls traditional biological research and development?

Before I cause too much anxiety in the wet laboratory-based scientific community, let me elucidate what I mean by computer-based research. My view is that it includes, but is not restricted to, what many of you may already be thinking, namely the growing field of bioinformatics.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Geoff Parker, Commercial Director at Scimcon

Geoff Parker is Commercial Director at scientific information management consultancy Scimcon, where he is responsible for global sales and customer support. Geoff has a particular focus on data management strategy consultancy and enjoys a hands-on role advising clients on their information system requirements and system selection.

Before joining Scimcon in June 2000, Geoff spent two years with laboratory information system provider Thermo LabSystems. Prior to working in the lab information systems field, Geoff had a background in chemistry, working as a Technical Chemist, after which he spent five years working for a major technology supplier.

spacer
Geoff Parker
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Leading pharma packaging companies commit to supply for Covid-19 fight

The CEOs of Gerresheimer, Stevanato Group, and SCHOTT are committed to ensuring ample supply of pharmaceutical containers for any Covid-19 vaccine and treatment that is developed, and that no patient shall be left behind, no matter what region of the world they live in.
More info >>

White Papers

Inhaler Adherence: Exploring Key Factors

Aptar Pharma

Aptar Pharma recently hosted an expert panel roundtable on “Inhaler Adherence”. This international scientific forum was held in Paris, France on November 29th 2013. The roundtable was organized to explore and exchange views on the issues which may influence inhaler adherence/ compliance with a particular focus on asthma and C.O.P.D. therapies and their corresponding inhaler devices (MDIs, DPIs).
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement